iShares Nasdaq Biotechnology ETF Stock Forecast, Price & News

Wall Street analysts have given iShares Nasdaq Biotechnology ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iShares Nasdaq Biotechnology ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

iShares Nasdaq Biotechnology ETF's stock was trading at $106.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IBB shares have increased by 40.2% and is now trading at $150.00.
View which stocks have been most impacted by COVID-19.

iShares Nasdaq Biotechnology ETF pays an annual dividend of $0.39 per share and currently has a dividend yield of 0.26%.
View iShares Nasdaq Biotechnology ETF's dividend history.

Shares of iShares Nasdaq Biotechnology ETF split on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

Some companies that are related to iShares Nasdaq Biotechnology ETF include iShares MSCI Emerging Markets ETF (EEM), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR Bloomberg Barclays High Yield Bond ETF (JNK), SPDR Nuveen Bloomberg Barclays Short Term Municipal Bond ETF (SHM), SPDR Nuveen Barclays Municipal Bond ETF (TFI), Direxion Daily Financial Bull 3X Shares (FAS), DNP Select Income Fund (DNP), iShares MSCI Pacific ex Japan ETF (EPP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), PIMCO Corporate & Income Opportunity Fund (PTY), Hercules Capital (HTGC), Goldman Sachs BDC (GSBD), WisdomTree Emerging Markets High Dividend Fund (DEM) and The Gabelli Equity Trust (GAB).
View all of IBB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares Nasdaq Biotechnology ETF investors own include NVIDIA (NVDA), The Walt Disney (DIS), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Cisco Systems (CSCO), Micron Technology (MU), Bank of America (BAC), Johnson & Johnson (JNJ) and PayPal (PYPL).

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

iShares Nasdaq Biotechnology ETF's stock is owned by many different institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (4.86%), Healthcare of Ontario Pension Plan Trust Fund (3.97%), JPMorgan Chase & Co. (3.14%), BNP Paribas Arbitrage SA (2.37%), Barclays PLC (1.80%) and Royal Bank of Canada (1.79%).

IBB stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Healthcare of Ontario Pension Plan Trust Fund, CHURCHILL MANAGEMENT Corp, Bank of Nova Scotia, Barclays PLC, Stifel Financial Corp, Mariner LLC, and Envestnet Asset Management Inc..

IBB stock was acquired by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, JPMorgan Chase & Co., Bell Bank, Wolverine Asset Management LLC, Atom Investors LP, Ergoteles LLC, Quantitative Investment Management LLC, and Q3 Asset Management.

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IBB stock can currently be purchased for approximately $150.00.

iShares Nasdaq Biotechnology ETF has a market capitalization of $10.06 billion.